Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Aug;36(2):105–108. doi: 10.1111/j.1365-2125.1993.tb04204.x

Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.

K Brøsen 1, E Skjelbo 1, H Flachs 1
PMCID: PMC1364572  PMID: 8398577

Abstract

1. A sparteine/mephenytoin phenotyping test was carried out in 37 Vietnamese living in Denmark. By visual inspection the urinary S/R-mephenytoin ratio appeared to show a bimodal frequency distribution. Eight putative poor metabolizers of mephenytoin, PMm (22%), had S/R-mephenytoin ratios from 0.79 to 1.12 and 29 putative extensive metabolizers of mephenytoin, EMm, had S/R-mephenytoin ratios < or = 0.55. All of the subjects were extensive metabolizers of sparteine with urinary metabolic ratios from 0.15 to 2.4. 2. The metabolism of the antimalarial prodrug proguanil was studied in 34 of the subjects after a single oral dose of 100 mg. The median 12 h urinary recoveries of the active metabolite cycloguanil and the minor metabolite 4-chlorphenylbiguanide were 5.8 and 1.9% of the dose, respectively, in 26 EMm compared with 1.6 and 0.4%, respectively, in 8 PMm (P < 0.001, Mann-Whitney U-test). 3. There was no statistically significant correlation (Spearmans rs) between any index of proguanil metabolism and the sparteine metabolic ratio.

Full text

PDF
105

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alván G., Bechtel P., Iselius L., Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol. 1990;39(6):533–537. doi: 10.1007/BF00316090. [DOI] [PubMed] [Google Scholar]
  2. Bertilsson L., Lou Y. Q., Du Y. L., Liu Y., Kuang T. Y., Liao X. M., Wang K. Y., Reviriego J., Iselius L., Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther. 1992 Apr;51(4):388–397. doi: 10.1038/clpt.1992.38. [DOI] [PubMed] [Google Scholar]
  3. Brøsen K., Otton S. V., Gram L. F. Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol (Copenh) 1985 Nov;57(5):357–360. doi: 10.1111/j.1600-0773.1985.tb00058.x. [DOI] [PubMed] [Google Scholar]
  4. CARRINGTON H. C., CROWTHER A. F., DAVEY D. G., LEVI A. A., ROSE F. L. A metabolite of paludrine with high antimalarial activity. Nature. 1951 Dec 22;168(4288):1080–1080. doi: 10.1038/1681080a0. [DOI] [PubMed] [Google Scholar]
  5. Clasen K., Madsen L., Brøsen K., Albøge K., Misfeldt S., Gram L. F. Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland. Clin Pharmacol Ther. 1991 Jun;49(6):624–631. doi: 10.1038/clpt.1991.79. [DOI] [PubMed] [Google Scholar]
  6. Drøhse A., Bathum L., Brøsen K., Gram L. F. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol. 1989 May;27(5):620–625. doi: 10.1111/j.1365-2125.1989.tb03426.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eichelbaum M., Bertilsson L., Säwe J., Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther. 1982 Feb;31(2):184–186. doi: 10.1038/clpt.1982.29. [DOI] [PubMed] [Google Scholar]
  8. Funck-Brentano C., Bosco O., Jacqz-Aigrain E., Keundjian A., Jaillon P. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. Clin Pharmacol Ther. 1992 May;51(5):507–512. doi: 10.1038/clpt.1992.55. [DOI] [PubMed] [Google Scholar]
  9. Furuya H., Meyer U. A., Gelboin H. V., Gonzalez F. J. Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA. Mol Pharmacol. 1991 Sep;40(3):375–382. [PubMed] [Google Scholar]
  10. Ged C., Umbenhauer D. R., Bellew T. M., Bork R. W., Srivastava P. K., Shinriki N., Lloyd R. S., Guengerich F. P. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase. Biochemistry. 1988 Sep 6;27(18):6929–6940. doi: 10.1021/bi00418a039. [DOI] [PubMed] [Google Scholar]
  11. Helsby N. A., Ward S. A., Howells R. E., Breckenridge A. M. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br J Clin Pharmacol. 1990 Aug;30(2):287–291. doi: 10.1111/j.1365-2125.1990.tb03777.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Horai Y., Nakano M., Ishizaki T., Ishikawa K., Zhou H. H., Zhou B. I., Liao C. L., Zhang L. M. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther. 1989 Aug;46(2):198–207. doi: 10.1038/clpt.1989.126. [DOI] [PubMed] [Google Scholar]
  13. Jackson P. R., Tucker G. T., Lennard M. S., Woods H. F. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol. 1986 Nov;22(5):541–550. doi: 10.1111/j.1365-2125.1986.tb02933.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jurima M., Inaba T., Kadar D., Kalow W. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol. 1985 Apr;19(4):483–487. doi: 10.1111/j.1365-2125.1985.tb02673.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Küpfer A., Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 1984;26(6):753–759. doi: 10.1007/BF00541938. [DOI] [PubMed] [Google Scholar]
  16. Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985 Oct;38(4):402–408. doi: 10.1038/clpt.1985.194. [DOI] [PubMed] [Google Scholar]
  17. Petersen E., Flachs H., Høgh B., Hanson A. P., Björkman A., Hvidberg E. F. Plasma, erythrocyte and urine concentrations of chlorproguanil and two metabolites in man after different doses. J Trop Med Hyg. 1991 Jun;94(3):199–205. [PubMed] [Google Scholar]
  18. Romkes M., Faletto M. B., Blaisdell J. A., Raucy J. L., Goldstein J. A. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry. 1991 Apr 2;30(13):3247–3255. doi: 10.1021/bi00227a012. [DOI] [PubMed] [Google Scholar]
  19. Sanz E. J., Villén T., Alm C., Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther. 1989 May;45(5):495–499. doi: 10.1038/clpt.1989.63. [DOI] [PubMed] [Google Scholar]
  20. Setiabudy R., Chiba K., Kusaka M., Ishizaki T. Caution in the use of a 100 mg dose of racemic mephenytoin for phenotyping southeastern Oriental subjects. Br J Clin Pharmacol. 1992 Jun;33(6):665–666. [PMC free article] [PubMed] [Google Scholar]
  21. Sohn D. R., Kusaka M., Ishizaki T., Shin S. G., Jang I. J., Shin J. G., Chiba K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther. 1992 Aug;52(2):160–169. doi: 10.1038/clpt.1992.125. [DOI] [PubMed] [Google Scholar]
  22. Vinks A., Inaba T., Otton S. V., Kalow W. Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther. 1982 Jan;31(1):23–29. doi: 10.1038/clpt.1982.4. [DOI] [PubMed] [Google Scholar]
  23. Ward S. A., Helsby N. A., Skjelbo E., Brøsen K., Gram L. F., Breckenridge A. M. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. Br J Clin Pharmacol. 1991 Jun;31(6):689–692. doi: 10.1111/j.1365-2125.1991.tb05594.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ward S. A., Watkins W. M., Mberu E., Saunders J. E., Koech D. K., Gilles H. M., Howells R. E., Breckenridge A. M. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol. 1989 Jun;27(6):781–787. doi: 10.1111/j.1365-2125.1989.tb03440.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wedlund P. J., Aslanian W. S., McAllister C. B., Wilkinson G. R., Branch R. A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther. 1984 Dec;36(6):773–780. doi: 10.1038/clpt.1984.256. [DOI] [PubMed] [Google Scholar]
  26. Zhang Y., Blouin R. A., McNamara P. J., Steinmetz J., Wedlund P. J. Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol. 1991 Mar;31(3):350–352. doi: 10.1111/j.1365-2125.1991.tb05542.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES